ConductScience.org, home

Paper28296257

Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.

Bowman SJ and 22 others. Arthritis Rheumatol, 2017. Cited by 217 papers, by iCite.

Cite this record

ConductScience Library. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. Papers, record 28296257. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28296257

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.
PubMed
Journal
Arthritis Rheumatol
PubMed
Year
2017
PubMed
Publication types
Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
217
iCite
Relative citation ratio, by iCite
9.47
iCite
Revised in PubMed
2026-01-27
PubMed

Authors23

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bowman SJSimon J
2Everett CCColin Chttps://orcid.org/0000-0002-9788-840X
3O'Dwyer JLJohn L
4Emery PPaul
5Pitzalis CCostantino
6Ng WFWan-Faihttps://orcid.org/0000-0002-5539-388X
7Pease CTColin T
8Price EJElizabeth J
9Sutcliffe NNurhan
10Gendi NSTNagui S T
11Hall FCFrances C
12Ruddock SPSharon P
13Fernandez CCatherine
14Reynolds CCatherine
15Hulme CTClaire T
16Davies KAKevin A
17Edwards CJChristopher J
18Lanyon PCPeter C
19Moots RJRobert J
20Roussou EEuthalia

Source PubMed

See all 23 authorsDownload CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antirheumatic AgentsMajor topic
FatigueMajor topic
RituximabMajor topic
Sjogren's SyndromeMajor topic
XerostomiaMajor topic
Adult
Aged
Cost-Benefit Analysis
Double-Blind Method
Female
Humans
Male
Middle Aged
Odds Ratio
Patient Reported Outcome Measures
Quality of Life
Quality-Adjusted Life Years
Treatment Outcome
United Kingdom
Visual Analog Scale

Source PubMed

Download CSV of topics

Grants7

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
MR/N003063/1Medical Research CouncilUnited KingdomPubMed
21268Versus ArthritisUnited KingdomPubMed
G0800629Medical Research CouncilUnited KingdomPubMed
18810Versus ArthritisUnited KingdomPubMed
RC-PG-0407-10054Department of HealthUnited KingdomPubMed
18475Arthritis Research UKUnited KingdomPubMed
20639Versus ArthritisUnited KingdomPubMed

Source PubMed

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT07145060A Study of Yiqi Yangyin Formula in the Treatment of Primary Sjogren's SyndromeResults

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Erratum in33460295Incorrect Data in Tables and Omission of Author Name in the Article by Bowman et al (Arthritis Rheumatol, July 2017).https://conductscience.org/library/papers/33460295PubMed
Comment in28296253Editorial: Rituximab in the Treatment of Sjögren's Syndrome: Is It the Right or Wrong Drug?https://conductscience.org/library/papers/28296253PubMed

Download CSV of comments and corrections

Cited by137

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 217 citations.

PMIDTitleJournalYearIn PapersSource
42970028A Systematic Literature Review on the Economic Burden of Sjögren's Disease.Pharmacoeconomics2026https://conductscience.org/library/papers/42970028PubMed
42941814Host-Microbe Crosstalk in Sjögren's Disease: Epithelial Type I Interferon Amplification, Loss of Short-Chain Fatty Acid Restraint, and the Effector-Phase Focus of Validated Therapy.Int J Mol Sci2026https://conductscience.org/library/papers/42941814PubMed
42857216Tregs transduced with a Ro60-reactive TCR have increased immunosuppressive functions in Sjögren's disease.iScience2026https://conductscience.org/library/papers/42857216PubMed
42840875Histone lactylation: a metabolic-epigenetic bridge linking glycolysis to salivary gland fibrosis in Sjögren's disease.Front Immunol2026https://conductscience.org/library/papers/42840875PubMed
42787283B-cell centrality dictates therapeutic efficacy across autoimmune diseases: a systematic review.Front Immunol2026https://conductscience.org/library/papers/42787283PubMed
42780594From immune activation to symptom burden: mechanisms and translational implications of immune-symptom uncoupling in Sjögren's disease.Front Immunol2026https://conductscience.org/library/papers/42780594PubMed
42528857Spatiotemporal orchestration of the salivary gland immune microenvironment in Sjögren's disease: a multidimensional framework of epithelial licensing, lymphoid neogenesis, and stromal remodeling.Front Immunol2026https://conductscience.org/library/papers/42528857PubMed
42488665Janus kinase inhibitor use and incident dry eye disease in rheumatoid arthritis: a real-world cohort study.Front Immunol2026https://conductscience.org/library/papers/42488665PubMed
42449965From Molecular Pathophysiology to Clinical Trial Design in Sjögren's Disease: A Three-Axis Framework.Int J Mol Sci2026https://conductscience.org/library/papers/42449965PubMed
42419786Integrating basal and reserve salivary function defines clinically anchored functional phenotypes and contextualises salivary end points in Sjögren's disease.RMD Open2026https://conductscience.org/library/papers/42419786PubMed
42414970Age-specific reference values for unstimulated whole saliva flow rate in primary Sjögren's syndrome: a cross-sectional study.BMC Oral Health2026https://conductscience.org/library/papers/42414970PubMed
42342283Emerging treatments for Sjögren's disease: promising drugs on the horizon.RMD Open2026https://conductscience.org/library/papers/42342283PubMed
42260594Molecular classification of primary Sjögren's syndrome based on salivary gland omics.Arthritis Res Ther2026https://conductscience.org/library/papers/42260594PubMed
42251196Fatigue in Sjögren's Disease - Integrating Biomedical and Psychosocial Aspects: A Narrative Review.Rheumatol Ther2026https://conductscience.org/library/papers/42251196PubMed
42194915When Dryness Extends to the Brain: Brain-Related Non-Sicca Manifestations of Sjögren's Disease.J Clin Med2026https://conductscience.org/library/papers/42194915PubMed
42123721Molecular Insights into Oral Manifestations in Sjögren's Disease.Int J Mol Sci2026https://conductscience.org/library/papers/42123721PubMed
42043506[Current treatment, foreseeable newcomer and new treatment approaches for Sjögren's disease].Z Rheumatol2026https://conductscience.org/library/papers/42043506PubMed
42008018The Evolving Landscape of CAR T-Cell Therapy in Autoimmune Diseases: A State-of-the-Art Review (2025).Clin Rev Allergy Immunol2026https://conductscience.org/library/papers/42008018PubMed
41922188[Research progress on the application of telitacicept in rheumatism and autoimmune diseases].Zhejiang Da Xue Xue Bao Yi Xue Ban2026https://conductscience.org/library/papers/41922188PubMed
41912841Evaluation of Effectiveness of Long-Term Therapy with Russian Rituximab Biosimilar (Acellbia) in Sjogren's Disease in Real Clinical Practice.Dokl Biochem Biophys2026https://conductscience.org/library/papers/41912841PubMed

See all 137 cited byDownload CSV of cited by

Data2

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccessionSource
EudraCT2010-021430-64PubMed
ISRCTN65360827ISRCTN

Download CSV of data

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • References
  • Genes
  • Drugs

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28296257

GET https://conductscience.org/api/papers/v1/28296257/authors?page=2